Project Name: Greater Glasgow & Clyde Chronic Myeloid Leukaemia (CML)/ Myeloproliferative Neoplasm (MPN) Service Development
Project period: 12 months
Joint working project summary: Novartis Oncology and NHS GGC have collaborated through a Joint Working Project to develop a MPN/CML Service at NHS Greater Glasgow and Clyde. Following the successful completion of the first year of the project the parties have agreed to continue their collaboration for an additional period to 1st August 2017.
The Project Extension shall aim at furthering and consolidating the objectives already achieved through the Project, and namely:
1) Improve support for patients with Myelo Proliferative Neoplasms (“MPNs”) and Chronic Myeloid Leukaemia (“CML”) by providing patient-centred care in accordance with the NHS Scotland Standards in Management of Core Cancer Services specifically by:
reducing the number of consultant clinic visits for CML and MPN patients by stratifying the patients and direct them to consultant -led or nurse-led clinics as appropriate;
if suitable, refer patients for clinical trials in CML and MPNs across NHS GGC, offering patients an equal access to clinical trials irrespective of their address. Patients can be referred in from other NHS GG&C and West of Scotland Cancer Network (WOSCAN) District General Hospitals.
Setting up a nurse-led telephone service to follow up non-complex patients.
2) Ongoing education of the MPN/CML HCPs team and their patients in the disease, adverse event management, treatment, treatment compliance and new developments.
3) Create a service sustainable business case through:
Share best practice with NHS Lothian CML/MPN Service Development, in particular the business plan development to ensure sustainable funding in NHS Lothian at the close of the project in September 2016. The learnings can then be used to support the NHS GGC business case for sustainable funding in September 2017.
Create a MPN database and further populate the existing CML patient database for the purposes of developing evidence to support a business case for the funding of the service by the NHS, dependant on numbers of patients identified (e.g. centralising the CML patients to the Beatson Oncology Centre (BOC) in 2015).
Expected patient outcomes for this project Outcome 1 (aligned to Objective 1): improve patient care, experience and satisfaction by developing a service that is patient-centric and focussed on the individual needs and requirements of the patients; improve patient concordance and adherence to treatment which will improve patient outcomes.
Outcome 2 (aligned to Objective 2). Empower both the MPN/CML HCPs team and their patient to make informed decisions around disease management by supporting the education of both the MPN/CML team HCPs and their patients.
Outcome 3 (aligned to Objective 3): Support the GGC MPN/CML team to become a high performing team and center of excellence for the treatment of MPNs and demonstrate service sustainability for NHS GGC.